HTB

Update to US saquinavir label

On 23 October the FDA approved label changes for the antiviral drug saquinavir (Invirase), describing a potential change in the electrical activity of the heart when saquinavir is used in combination with ritonavir. Changes in the electrical activity of the heart may lead to abnormal heart rhythms.

The Dear Doctor letter for this change was included in the September/October issue of HTB.

Links:

Revised saquinavir label

http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020628s033,021785s010lbl.pdf

Roche issue Dear Doctor letter: Saquinavir prolongation of QT interval. HIV Treatment Bulletin, September/October 2010.

http://i-base.info/htb/13984

Links to other websites are current at date of posting but not maintained.